NO941929L - Tokotrienoler og tokotrienol-lignende sammensetninger og fremgangsmåter for deres anvendelse - Google Patents

Tokotrienoler og tokotrienol-lignende sammensetninger og fremgangsmåter for deres anvendelse

Info

Publication number
NO941929L
NO941929L NO941929A NO941929A NO941929L NO 941929 L NO941929 L NO 941929L NO 941929 A NO941929 A NO 941929A NO 941929 A NO941929 A NO 941929A NO 941929 L NO941929 L NO 941929L
Authority
NO
Norway
Prior art keywords
tokotrienols
tocotrienol
compositions
methods
Prior art date
Application number
NO941929A
Other languages
English (en)
Other versions
NO301223B1 (no
NO941929D0 (no
Inventor
Ronald H Lane
Asaf A Qureshi
Winston A Salser
Original Assignee
Lipogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipogenics Inc filed Critical Lipogenics Inc
Publication of NO941929D0 publication Critical patent/NO941929D0/no
Publication of NO941929L publication Critical patent/NO941929L/no
Publication of NO301223B1 publication Critical patent/NO301223B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
    • C11B3/00—Refining fats or fatty oils
    • C11B3/001—Refining fats or fatty oils by a combination of two or more of the means hereafter
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/174—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
    • C11B1/00—Production of fats or fatty oils from raw materials
    • C11B1/02—Pretreatment
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
    • C11B1/00—Production of fats or fatty oils from raw materials
    • C11B1/10—Production of fats or fatty oils from raw materials by extracting
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Wood Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO941929A 1991-11-22 1994-05-24 Tokotrienoler og tokotrienollignende forbindelser og deres anvendelser NO301223B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79648691A 1991-11-22 1991-11-22
PCT/US1992/010277 WO1993009777A1 (en) 1991-11-22 1992-11-20 Tocotrienols and tocotrienol-like compounds and methods for their use

Publications (3)

Publication Number Publication Date
NO941929D0 NO941929D0 (no) 1994-05-24
NO941929L true NO941929L (no) 1994-07-13
NO301223B1 NO301223B1 (no) 1997-09-29

Family

ID=25168301

Family Applications (1)

Application Number Title Priority Date Filing Date
NO941929A NO301223B1 (no) 1991-11-22 1994-05-24 Tokotrienoler og tokotrienollignende forbindelser og deres anvendelser

Country Status (10)

Country Link
US (6) US5591772A (no)
EP (1) EP0543417A1 (no)
JP (2) JPH07504887A (no)
CN (1) CN1073357A (no)
CA (1) CA2124086A1 (no)
MX (1) MX9206735A (no)
MY (1) MY109856A (no)
NO (1) NO301223B1 (no)
SG (1) SG48108A1 (no)
WO (1) WO1993009777A1 (no)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1079795C (zh) * 1990-05-23 2002-02-27 利波吉尼克斯有限公司 稳定和回收生育三烯酚和生育酚产物的方法
EP0543417A1 (en) * 1991-11-22 1993-05-26 Lipogenics, Incorporated Tocotrienols and tocotrienol-like compounds and methods for their use
DE4222509A1 (de) * 1992-07-09 1994-01-13 Wilhelm Lange Mischfutter
TW393475B (en) * 1992-10-16 2000-06-11 Chugai Pharmaceutical Co Ltd 4-alkoxyl-2,6-di-t-butyl phenol derivatives
US5662934A (en) * 1993-01-05 1997-09-02 Najarian; Thomas Compositions and methods for lowering cholesterol while maintaining antioxidant levels
JP3839071B2 (ja) * 1993-12-07 2006-11-01 有限会社ケムフィズ クロマン誘導体
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
US6060101A (en) * 1994-09-02 2000-05-09 Designing Health, Inc. Dietary food supplement
US6007860A (en) * 1994-09-02 1999-12-28 Designing Health, Inc. Preparing food supplement
US5656312A (en) * 1994-09-02 1997-08-12 Erasmus; Udo Dietary food supplement and method of preparing
EP0828434B1 (en) * 1995-06-01 2000-02-09 Unilever N.V. Fat based food products
US20020086380A1 (en) * 1996-03-29 2002-07-04 Francis X. Cunningham Jr Genes encoding epsilon lycopene cyclase and method for producing bicyclic carotene
AU6886896A (en) * 1996-08-28 1998-03-19 Farmacon, Inc. Phenylbutanol derivatives, methods for their preparation and pharmaceutical compositions thereof
BR9808157A (pt) * 1997-03-04 2000-03-28 Wisconsin Alumni Res Found Processo de inibição do desenvolvimento de células tumorais e de tumor e composição farmacêutica
NZ520176A (en) * 1997-07-31 2005-02-25 Kos Life Sciences Inc Combinations of HMG-CoA reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night
AU8768098A (en) * 1997-08-04 1999-02-22 Christopher J. Berry Method of treating disease using a tocotrienol and alpha-lipoic acid r derivatives or an ester thereof
NZ503648A (en) * 1997-08-29 2002-10-25 Ricex Company Inc Process for preparing enzyme treated stabilised rice bran derivatives and their use in the treatment of diabetes, hyperglycemia and hypoglycemia
US5985344A (en) * 1997-09-02 1999-11-16 The Ricex Company Process for obtaining micronutrient enriched rice bran oil
AU9209898A (en) 1997-09-02 1999-03-22 Ricex Company, Inc., The A method for treating hypercholesterolemia, hyperlipidemia, and atherosclerosis
US6239114B1 (en) * 1997-09-26 2001-05-29 Kgk Synergize Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols
US6147109A (en) * 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
DE19750422C1 (de) * 1997-11-14 1998-11-26 Henkel Kgaa Verwendung von ausgewählten Phytostenolestern zur Herstellung von hypocholesterinämischen Mitteln
ID26335A (id) * 1997-11-17 2000-12-14 Lipogenic Inc Metoda untuk mencegah restenosis dengan menggunakan tokotrienol
CA2318218A1 (en) * 1998-01-12 1999-07-15 Howard F. Schneider Methods for treating diabetic dyslipidemia using tocotrienols
US6180597B1 (en) 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
GB9808796D0 (en) * 1998-04-24 1998-06-24 Rowett Research Services Limit Antithrombotic agents
US6410521B1 (en) * 1998-06-12 2002-06-25 Osteoscreen, Inc. Nutritional supplements for stimulating bone growth
US6531303B1 (en) * 1998-07-06 2003-03-11 Arkion Life Sciences Llc Method of producing geranylgeraniol
US6410755B1 (en) 1998-07-06 2002-06-25 Dcv, Inc. Method of vitamin production
EP1095034A1 (en) 1998-07-06 2001-05-02 Eastman Chemical Company Preparation of tocopherols
US6423751B1 (en) 1998-07-14 2002-07-23 The Brigham And Women's Hospital, Inc. Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
DE19835850A1 (de) * 1998-08-07 2000-02-10 Basf Ag Verwendung von Hemmstoffen der HMG-CoA-Reduktase zur Senkung des Cholesteringehaltes in Geflügelei
US5869704A (en) * 1998-08-24 1999-02-09 Eastman Chemical Company Water-dispersible or water-soluble D-tocotrienol compounds and methods for making therefor
WO2000015201A2 (en) * 1998-09-10 2000-03-23 Forbes Medi-Tech Inc. Compositions comprising one or more phytosterols, phytostanols or mixtures of both and one or more alpha, beta, delta, or gamma tocotrienols or derivatives thereof and use of the compositions in treating or preventing cardiovascular disease, its underlying conditions and other disorders
US6703384B2 (en) * 1998-09-23 2004-03-09 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
US6987125B1 (en) * 1998-10-06 2006-01-17 The United States Of America As Represented By The Secretary Of Agriculture Compositions and methods of treating, reducing and preventing cardiovascular diseases and disorders with polymethoxyflavones
US6277431B1 (en) 1998-10-14 2001-08-21 Redeem, Inc. Anticholesterolemic edible oil
AU1932900A (en) 1998-12-04 2000-06-26 Medivas, Llc Methods for detection of vulnerable plaques using a detectable lipid-avid agent
US6303500B1 (en) * 1999-02-24 2001-10-16 Micron Technology, Inc. Method and apparatus for electroless plating a contact pad
US6213930B1 (en) * 1999-03-15 2001-04-10 Wisconsin Alumni Research Foundation Method of using anti-phospholipase A2 antibodies to enhance growth or improve feed efficiency
AU3913800A (en) * 1999-03-26 2000-10-16 Lipogenics, Inc. Novel antioxidant formulations and methods for using them
US6616942B1 (en) * 1999-03-29 2003-09-09 Soft Gel Technologies, Inc. Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
US6632443B2 (en) 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US20080070981A1 (en) 2000-02-23 2008-03-20 Henryk Borowy-Borowski Water-soluble compositions of bioactive lipophilic compounds
US6350453B1 (en) 1999-05-24 2002-02-26 American River Nutrition, Inc. Tocotrienols and geranylgeraniol from Bixa orellana byproducts
AU5594700A (en) 1999-06-01 2000-12-18 Ocean Spray Cranberries, Inc. Cranberry seed oil extract and compositions containing components thereof
US6716451B1 (en) * 1999-11-30 2004-04-06 Soft Gel Technologies, Inc. Formulation and delivery method to enhance antioxidant potency of vitamin E
JP2001181191A (ja) * 1999-12-24 2001-07-03 Cci Corp 慢性関節リウマチ疾患予防および治療剤
AU2001232245A1 (en) * 2000-02-10 2001-08-20 Takeda Chemical Industries Ltd. Tnf- alpha inhibitors
RU2263672C2 (ru) * 2000-02-11 2005-11-10 Рисерч Дивелопмент Фаундейшн Токоферолы, токотриенолы, другие хроманы и производные по боковым цепям и их применение
CA2402273A1 (en) * 2000-03-08 2001-09-13 Vdf Futureceuticals Methods and compositions for dietary supplements
DE10035352A1 (de) * 2000-07-20 2002-01-31 Zlb Bioplasma Ag Bern Verfahren zur Behandlung von instabiler Angina pectoris
EP1199075B1 (en) 2000-09-27 2007-04-18 Eisai R&D Management Co., Ltd. The use of gamma-CEHC as antioxidants
JP4693140B2 (ja) * 2000-10-06 2011-06-01 富士化学工業株式会社 トコトリエノール含有医薬用剤
AUPR549901A0 (en) * 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
CA2426885C (en) * 2000-11-14 2010-06-29 Vital Health Sciences Pty Ltd Complexes of phosphate derivatives
US6838104B2 (en) * 2000-12-20 2005-01-04 Archer Daniels Midland Company Process for the production of tocotrienols
WO2002072035A2 (en) * 2001-03-14 2002-09-19 Lipogenics, Inc. Novel anti-inflammatory compositions and methods of use
AU2002307237A1 (en) * 2001-03-23 2002-10-08 Sonus Pharmaceuticals, Inc. Carboxybenzopyran derivatives and compositions
US6998421B2 (en) 2001-06-07 2006-02-14 Biozone Laboratories, Inc. Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase - 2
US6495596B1 (en) 2001-03-23 2002-12-17 Biozibe Laboratories, Inc. Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase-2
US7816398B2 (en) * 2001-03-23 2010-10-19 Luitpold Pharmaceuticals, Inc. Fatty alcohol drug conjugates
US6902739B2 (en) * 2001-07-23 2005-06-07 Nutracea Methods for treating joint inflammation, pain, and loss of mobility
WO2003011303A1 (en) * 2001-07-27 2003-02-13 Vital Health Sciences Pty Ltd Dermal therapy using phosphate derivatives of electron transfer agents
AUPR684801A0 (en) * 2001-08-06 2001-08-30 Vital Health Sciences Pty Ltd Supplement therapy
JP2005501094A (ja) * 2001-08-21 2005-01-13 ガリレオ ファーマシューティカルズ， インコーポレイティド トコフェロール富化組成物および炎症性症状の回復
WO2003037884A2 (en) * 2001-09-19 2003-05-08 Archer-Daniels-Midland Company Process for separation of tocopherols
US20030144219A1 (en) * 2001-11-15 2003-07-31 Phinney Stephen Dodge Formulations and methods for treatment or amelioration of inflammatory conditions
EP1460995B1 (en) * 2001-12-13 2010-11-10 Vital Health Sciences Pty Ltd. Transdermal transport of compounds
US20030236301A1 (en) * 2001-12-19 2003-12-25 Bob Sanders Liposomal delivery of vitamin E based compounds
EP1461069A2 (en) * 2001-12-29 2004-09-29 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
WO2003068156A2 (en) * 2002-02-13 2003-08-21 Ritchie Shoemaker Methods for treating or inhibiting sick building syndrome, post-lyme disease syndrome, and/or chronic fatigue syndrome
US20100041079A1 (en) * 2002-03-24 2010-02-18 Mcmaster University Method for predicting cardiovascular events
MY139332A (en) * 2002-05-22 2009-09-30 Hovid Berhad Hair growth formulation
EP1517667A2 (en) * 2002-07-02 2005-03-30 Galileo Pharmaceuticals, Inc. Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects
AU2002950713A0 (en) * 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
AU2003268235A1 (en) * 2002-09-09 2004-03-29 Mitochroma Research, Inc. Compositions and methods for treating niddm and other conditions and disorders associated with ampk regulation
US20040047946A1 (en) * 2002-09-10 2004-03-11 Kapac, Llc Methods and formulations useful for lowering the cholesterol content of egg yolk
JP2004171733A (ja) * 2002-11-06 2004-06-17 Alps Electric Co Ltd 磁気ヘッドおよびそれを備えた磁気テープ装置ならびに磁気ヘッドの製造方法
US20040102421A1 (en) * 2002-11-21 2004-05-27 Children's Hospital Research Center At Oakland Tocopherol and tocotrienol anti-inflammatory medicaments
US7329688B2 (en) * 2002-12-17 2008-02-12 Soft Gel Technologies, Inc. Natural vitamin E compositions with superior antioxidant potency
JP4690305B2 (ja) * 2003-01-17 2011-06-01 バイタル ヘルス サイエンシズ プロプライアタリー リミティド 抗増殖性質を有する化合物
US7989006B2 (en) * 2003-04-08 2011-08-02 American River Nutrition, Inc. Annatto extract compositions, including geranyl geraniols and methods of use
WO2004096137A2 (en) * 2003-04-08 2004-11-11 Barrie Tan Annatto extract compositions, including geranyl geraniols and methods of use
US20050037102A1 (en) * 2003-07-18 2005-02-17 Barrie Tan Annatto extract compositions including tocotrienols and tocopherols and methods of use
EP1617724B1 (en) * 2003-04-10 2014-08-20 Barrie Tan Annatto extract compositions including tocotrienols and tocopherols and methods of use
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
US20040266862A1 (en) * 2003-06-25 2004-12-30 Wolf Fred R. Method of improving animal tissue quality by supplementing the animal diet with mixed tocotrienols
EP1660075A2 (en) * 2003-08-08 2006-05-31 The Ohio State University Research Foundation Protective and therapeutic uses for tocotrienols
US20080089877A1 (en) * 2003-08-14 2008-04-17 Udell Ronald G Super Absorption Coenzyme Q10
US7416756B2 (en) * 2003-09-10 2008-08-26 Eastman Chemical Company Process for the recovery of a phytolipid composition
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
JP4334956B2 (ja) * 2003-09-18 2009-09-30 株式会社ノエビア 細胞賦活剤、美白剤、及び抗酸化剤
WO2005033093A1 (en) * 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. 7,8-bicycloalkyl-chroman derivatives
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
AU2004277951B2 (en) 2003-09-29 2010-11-11 Soft Gel Technologies, Inc. Solubilized CoQ-10
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
US20050107465A1 (en) * 2003-10-01 2005-05-19 Papas Andreas M. Composition for treating inflammatory bowel disease
DE602005025979D1 (de) 2004-03-03 2011-03-03 Vital Health Sciences Pty Ltd Alkaloid-formulierungen
US7872042B2 (en) * 2004-05-14 2011-01-18 Rubin Berish Y Use of tocotrienols for elevating IKBKAP gene expression and treating Familial Dysautonomia
ATE417513T1 (de) * 2004-06-15 2009-01-15 Du Pont Verfahren zur verbesserung der qualität von tierischem gewebe durch ergänzen der ration des tiers mit ölsäure und ausgewählten tocolen
US20080063625A1 (en) * 2004-07-30 2008-03-13 Cel-Sci Corporation Method for Managing Cholesterol with a Serum-Free and Mitogen-Free Cytokine Mixture
EP2269650A3 (en) * 2004-08-03 2012-05-16 Vital Health Sciences Pty Ltd. Carrier for enteral administration
US20060093592A1 (en) * 2004-10-04 2006-05-04 Nutracea Synbiotics
WO2006065686A2 (en) 2004-12-13 2006-06-22 Galileo Pharmaceuticals, Inc. Spiro derivatives as lipoxygenase inhibitors
MX2007010327A (es) * 2005-02-25 2007-10-16 Lilly Co Eli Inhibidores de lipoxigenasa novedosos.
BRPI0520097A2 (pt) 2005-02-25 2009-08-25 Lilly Co Eli composto ou estereoisÈmeros únicos, misturas de estereoisÈmeros, ou sais farmaceuticamente aceitáveis dos mesmos, composição farmacêutica, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
US20090239827A1 (en) * 2005-03-03 2009-09-24 Esra Ogru Compounds having lipid lowering properties
JP2008513350A (ja) * 2005-05-24 2008-05-01 ケージーケー シナジャイズ インコーポレイテッド フラボノイドとトコトリエノールを含む組成物及びその方法
PL1888059T3 (pl) 2005-06-01 2015-06-30 Bioelectron Tech Corp Środki terapeutyczne aktywne wobec układów redoks do leczenia chorób mitochondrialnych i innych zaburzeń oraz modulacja biomarkerów energetycznych
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
US20070021497A1 (en) * 2005-07-11 2007-01-25 The Fruitful Yield Vitamin e compositions
WO2007093853A2 (en) * 2005-11-10 2007-08-23 Kgk Synergize Inc Compositions and methods for treatment and prevention of metabolic syndrome and its associated conditions with combinations of flavonoids, liminoids and tocotrienols
JP2009520697A (ja) * 2005-12-23 2009-05-28 バイタル ヘルス サイエンシズ プロプライアタリー リミティド サイトカイン調節性を有する化合物
EP1986636B1 (en) 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases
US8288369B2 (en) * 2006-06-27 2012-10-16 University Of South Florida Delta-tocotrienol treatment and prevention of pancreatic cancer
US8343541B2 (en) 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
US20090155439A1 (en) * 2007-12-14 2009-06-18 Leo Gingras Mechanical extrusion process for stabilizing cereal and oil seed bran and germ components
EP2268274B1 (en) * 2008-03-20 2012-05-16 Virun, Inc. Vitamin e derivatives and their uses
CN102036572A (zh) 2008-03-20 2011-04-27 维尔恩公司 包含生育酚的peg衍生物的乳剂
EP2344142B1 (en) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
PL2362875T3 (pl) 2008-10-28 2016-01-29 Bioelectron Tech Corp Proces do wytwarzania alfa-tokotrienolu i pochodnych
SI2424495T1 (en) 2009-04-28 2018-04-30 Bioelectron Technology Corporation TREATMENT OF LEEBER HEREDITARY OPTICAL NEVROPATY AND DOMINANT OPTICAL ATROPHY WITH TOKOTRIENOL KINONA
JP2012531411A (ja) 2009-06-25 2012-12-10 アンペア ライフ サイエンシーズ，インコーポレイテッド トコトリエノールまたはトコトリエノール濃縮抽出物を用いた広汎性発達障害の処置
KR100982032B1 (ko) * 2009-12-29 2010-09-13 한국건설기술연구원 왕겨를 이용한 펠렛의 제조방법
EP2531047A4 (en) 2010-02-05 2014-03-19 Phosphagenics Ltd CARRIER WITH AN UNINUTRALIZED TOCOPHERYL PHOSPHATE
US8969303B2 (en) * 2010-02-05 2015-03-03 First Tech International Limited Tocotrienol esters
EP2563164B1 (en) * 2010-03-23 2016-06-29 Virun, Inc. Nanoemulsion including sucrose fatty acid ester
ES2829386T3 (es) 2010-03-30 2021-05-31 Phosphagenics Ltd Parche de administración transdérmica
US8741373B2 (en) 2010-06-21 2014-06-03 Virun, Inc. Compositions containing non-polar compounds
US20120295985A1 (en) * 2010-11-19 2012-11-22 Miller Guy M Methods for improving blood glucose control
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
WO2012154613A1 (en) * 2011-05-06 2012-11-15 Edison Pharmaceuticals, Inc. Improved process for the preparation of d-alpha-tocotrienol from natural extracts
JP2014520894A (ja) 2011-07-19 2014-08-25 エジソン ファーマシューティカルズ， インコーポレイテッド 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法
US10874635B2 (en) * 2011-10-21 2020-12-29 First Tech International Limited Tocotrienol compositions
JP2015503418A (ja) * 2012-01-09 2015-02-02 エイチ． デビッド ヒュームズ 心筋機能を向上させるためのカートリッジおよび方法
EP2858643A4 (en) * 2012-06-08 2015-11-11 Univ Ohio State METHOD AND COMPOSITIONS FOR IMPROVING THE PIA COLLATERAL CIRCUIT AND TREATING BLOOD CLEANING DISORDER
WO2013185024A1 (en) 2012-06-08 2013-12-12 The Ohio State University Treating burn and scar injury using tocotrienol
EP2877171A4 (en) * 2012-07-19 2016-01-13 Univ Ohio State METHOD FOR IMPROVING BLOOD GENERATION DISORDERS AND RELATED MATERIALS AND METHODS THEREFOR
WO2014075135A1 (en) * 2012-11-13 2014-05-22 Gordagen Pharmaceuticals Pty Ltd Transmucosal delivery of tocotrienol
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
KR20160068776A (ko) 2013-09-13 2016-06-15 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 방사선 효과의 완화 및 예방을 위한 조성물의 제조 및 용도
US9512098B1 (en) 2014-02-03 2016-12-06 Board Of Trustees Of The University Of Arkansas Process of producing purified gamma- and delta-tocotrienols from tocol-rich oils or distillates
CN104000196B (zh) * 2014-06-04 2016-03-16 李�杰 复方牡丹籽油制剂及制备方法和应用
US20160324914A1 (en) 2015-05-05 2016-11-10 Tocol Pharmaceuticals, Llc Use of rice bran oil distillate extract for prevention and mitigation of the effects of radiation
JP2018522950A (ja) * 2015-08-11 2018-08-16 杉山　理 血液循環の改善及びミトコンドリアエネルギー産生の維持のためのシステム並びに方法
EP3383371B1 (en) 2015-12-09 2024-05-01 Avecho Biotechnology Limited Pharmaceutical formulation
US10745371B2 (en) 2015-12-16 2020-08-18 Ptc Therapeutics, Inc. Methods for enriching alpha-tocotrienol from mixed tocol compositions
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
US10377792B2 (en) * 2016-03-16 2019-08-13 The Texas A&M University System Moisture displacement and simultaneous migration of surface-functionalized algae from water to an extraction solvent using ionic polyelectrolytes
CA3045702A1 (en) 2016-12-21 2018-06-28 Phosphagenics Limited Phosphorylation process of complex alcohols
CN111574486B (zh) * 2020-05-22 2022-04-26 中国科学院南海海洋研究所 香叶基三羟基色酮及其在制备肝x受体激动剂中的应用
EP4274566A1 (en) * 2021-01-06 2023-11-15 The Trustees of Indiana University Tocotrienol compositions and methods to treat non-alcoholic steatohepatitis
CN116354916B (zh) * 2021-12-27 2024-07-19 深圳大学 具有改善胰岛素抵抗作用的化合物或其药学上可接受的盐及其制备方法和应用
CN115385885A (zh) * 2022-05-05 2022-11-25 深圳海创生物科技有限公司 一种蓝莓多酚、组合物及其在制备具有降血脂和/或减肥作用的药物或食品中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB870638A (en) * 1958-11-07 1961-06-14 Hoffmann La Roche Derivatives of 2,3-dimethoxy-5-methyl benzohydroquinone-(1,4) and a process for the manufacture thereof
US3026330A (en) * 1960-05-09 1962-03-20 Merck & Co Inc Chroman compounds having antioxidant activity
US3064012A (en) * 1960-07-20 1962-11-13 Merck & Co Inc Derivatives of coenzyme q10
US3122565A (en) * 1960-10-22 1964-02-25 Eisai Co Ltd Purification process of tocopherol containing materials
CH424801A (de) * 1963-07-04 1966-11-30 Hoffmann La Roche Verfahren zur Herstellung von Chromanverbindungen
CH619701A5 (no) * 1975-08-07 1980-10-15 Bayer Ag
DE3221506A1 (de) * 1982-06-07 1983-12-08 Karl Heinz Dipl.-Chem. Dr. 8011 Vaterstetten Dötz Verfahren zur herstellung von tocopherolen und ubichinonen, zwischenprodukte dieses verfahrens und deren verwendung hierin
US4603143A (en) * 1983-05-02 1986-07-29 Basf Corporation Free-flowing, high density, fat soluble vitamin powders with improved stability
US5034420A (en) * 1983-06-09 1991-07-23 Bristol-Myers Squibb Co. Compositions and method for stabilization of anthralin comprising the addition of an oil soluble antioxidant and an anionic surfactant
GB2152837B (en) * 1983-07-05 1987-03-25 Kuraray Co Extractive separation method
ES2067461T3 (es) * 1987-08-25 1995-04-01 Nisshin Flour Milling Co Derivados isoprenoides y agentes anti-ulcerosos que contienen los mismos.
US4788304A (en) * 1987-12-07 1988-11-29 American Home Products Corporation Phospholipase A2 inhibitors
JP2785035B2 (ja) * 1989-04-06 1998-08-13 日清製油株式会社 化粧料および外用剤
KR910007523A (ko) * 1989-10-04 1991-05-30 브리스톨-마이어즈 스퀴브 컴페니 과콜레스테린혈증, 과지방혈증 및 혈전색전증 질병 치료용 토코트리엔올
US5217992A (en) * 1989-10-04 1993-06-08 Bristol-Myers Squibb Company Tocotrienols in the treatment of hypercholesterolemia, hyperlipidemia and thromboembolic disorders
US5393776A (en) * 1990-09-14 1995-02-28 Bristol-Myers Squibb Company Tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia
US5204373A (en) * 1991-08-26 1993-04-20 Bristol-Myers Squibb Company Farnesylated tetrahydro-naphthalenols as hypolipidemic agents
EP0543417A1 (en) * 1991-11-22 1993-05-26 Lipogenics, Incorporated Tocotrienols and tocotrienol-like compounds and methods for their use

Also Published As

Publication number Publication date
CN1073357A (zh) 1993-06-23
US6143770A (en) 2000-11-07
US5821264A (en) 1998-10-13
US5591772A (en) 1997-01-07
JPH07504887A (ja) 1995-06-01
US5919818A (en) 1999-07-06
SG48108A1 (en) 1998-04-17
AU670557B2 (en) 1996-07-25
JP2000169369A (ja) 2000-06-20
US6204290B1 (en) 2001-03-20
MY109856A (en) 1997-09-30
EP0543417A1 (en) 1993-05-26
NO301223B1 (no) 1997-09-29
MX9206735A (es) 1993-05-01
NO941929D0 (no) 1994-05-24
CA2124086A1 (en) 1993-05-27
US6239171B1 (en) 2001-05-29
AU3150293A (en) 1993-06-15
WO1993009777A1 (en) 1993-05-27

Similar Documents

Publication Publication Date Title
NO941929L (no) Tokotrienoler og tokotrienol-lignende sammensetninger og fremgangsmåter for deres anvendelse
DK543189D0 (da) Lysyloxidaseinhibitorer og deres anvendelse
DK0384288T3 (da) Piperidinforbindelser og deres fremstilling og anvendelse
NO941161D0 (no) Flyveaske-sementeringssammensetninger og metoder
NO942193D0 (no) Metallocener og fremgangsmåte til deres fremstilling og bruk
DK527789D0 (da) Dithiocarbamoylquinoloner og sammensaetninger omfattende samme
NO954239D0 (no) Heterocykliske forbindelser og deres fremstilling og anvendelse
DK0623015T3 (da) Adhæsivsammensætning og fremgangsmåde
DK0395988T3 (da) Pigmentsammensætninger og deres anvendelse
NO931496D0 (no) Kaks-sementsammensetninger og fremgangsmaater for anvendelse derav
NO893196D0 (no) Hybrid-protein-c-sammensetninger og fremgangsmaater for deres fremstilling.
NO942301D0 (no) Imidazokinazolinforbindelser og deres fremstilling og anvendelse
DK4491D0 (da) Aclonifen-baserede herbicidblandinger og deres anvendelse
DK45188D0 (da) Substituerede aminderivater og deres anvendelse
NO954763D0 (no) Piperidinderivater, deres fremstilling og anvendelse
DE69225104D1 (de) PCT-Zusammensetzung
DK73091D0 (da) Quinoxalinforbindelser, deres fremstilling og anvendelse
DK360189D0 (da) S-adenosyl-methionin-decarboxylase-inhibitorer, deres fremstilling og anvendelse
NO921834L (no) Smerteregulerende sammensetning og fremgangsmaate for fremstilling
NO922992D0 (no) Imid-terminerte polynitrogenforbindelser, deres fremstilling og anvendelse
NO921878D0 (no) Nitrittoksyderte lignosulfonater og fremgangsmaate for deres fremstilling
DK634089A (da) Polyhydroxybenzyloxypropanolaminer og deres anvendelse
DE69225266D1 (de) Bis-bibenzimidazol Zusammensetzung
BR9202742A (pt) Composicao delimpeza
FI925175A0 (fi) Kompositioner haerdbara medelst straolning

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN MAY 2002